Table 1.

Comorbidities of patients with CD and controls at baseline.

	Controls	Cushing’s Disease	p
	(No. = 48)	(No. = 50)
	Subjects (%)	Subjects (%)
Gender
Male	9 (18.7%)	7 (14%)	0.475
Female	39 (81.3%)	43 (86%)
Arterial hypertension	18 (37.5%)	32 (64%)	0.009
Osteoporosis/osteopenia	7 (14.6%)	21 (42%)	0.002
Visceral obesity	38 (79.1%)	44 (88%)	0.224
Metabolic syndrome	19 (39.6%)	29 (58%)	0.069
Hypercholesterolemia	14 (29.1%)	30 (60%)	0.002
Hypertriglyceridemia	11 (22.9%)	13 (26%)	0.486
Low HDL	14 (29.1%)	19 (38%)	0.361
Cardiovascular disease	0	5 (10%)	0.118
Peripheral vascular disease	0	1 (2%)	0.489
Diabetes mellitus	6 (12.5%)	24 (48%)	0.026
IFG	0	6 (12%)	0.622
IGT	6 (12.5%)	7 (14%)	0.678
IFG + IGT	1 (2%)	3 (6%)	0.457
Moon face	24 (50%)	33 (66%)	0.108
Myopathy	12 (25%)	36 (72%)	<0.001
Facial rubor	9 (18.7%)	23 (46%)	0.005
Buffalo hump	17 (35.4%)	33 (66%)	0.002
Purple striae	11 (22.9%)	15 (30%)	0.245
Hypovitaminosis D
Deficiency	4 (8.4%)	26 (52%)	0.001
Insufficiency	10 (20.8%)	14 (28%)	0.545
Sufficiency	34 (70.8%)	10 (20%)	0.004